<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961944</url>
  </required_header>
  <id_info>
    <org_study_id>EVITA BI 1199-0430</org_study_id>
    <nct_id>NCT04961944</nct_id>
  </id_info>
  <brief_title>HypErsensitiVity PneumonITis: DiseAse Progression Characterization</brief_title>
  <acronym>EVITA</acronym>
  <official_title>HypErsensitiVity PneumonITis: DiseAse Progression Characterization. An International Multicentric Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EVITA is a multicentric Latin-American prospective study on hypersensitivity pneumonitis.&#xD;
      EVITA's objective is to identify phenotypes and/or endotypes associated with different&#xD;
      disease trajectories measured primarily by forced vital capacity (FVC) during a 24 month&#xD;
      follow-up period. Other secondary measures of disease progression will also be investigated&#xD;
      such as imaging, time to death or lung transplantation, and patient-reported outcomes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>24 months</time_frame>
    <description>as a continuous variable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung Densitometry</measure>
    <time_frame>24 months</time_frame>
    <description>Computed Tomography imaging progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or lung transplantation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute exacerbation rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>King´s Brief Interstitial Lung Disease Questionnaire (K-BILD)</measure>
    <time_frame>24 months</time_frame>
    <description>Health-related quality of Life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tests for interaction:</measure>
    <time_frame>24 months</time_frame>
    <description>1. Ag exposure remediation vs non-remediation; Treated vs non-treated HP (antifibrotics); 2. Stratification per sex; 3. Primary outcome dichotomized at loss of FVC &gt;= 10% predicted vs. &lt; 10% , and 4. FVC loss &gt;= 5% vs &lt; 5%.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypersensitivity Pneumonitis</condition>
  <arm_group>
    <arm_group_label>Hypersensitivity pneumonitis</arm_group_label>
    <description>see elegibility criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Disease assessment</intervention_name>
    <description>A comprehensive evaluation of the disease's extension, its impact on function, quality of life, and the search for phenotype/endotypes will be performed.&#xD;
The association between endotypes and disease progression will be tested.</description>
    <arm_group_label>Hypersensitivity pneumonitis</arm_group_label>
    <other_name>Pulmonary function test (PFT)</other_name>
    <other_name>High Resolution Computed Tomography (HRCT) of the Chest</other_name>
    <other_name>6-minute walking distance (6MWD)</other_name>
    <other_name>blood for genomics, functional genomics and protein biomarker analysis</other_name>
    <other_name>urine collection for protein biomarker analysis</other_name>
    <other_name>Bronchoalveolar fluid collection (in a subset of the sample)</other_name>
    <other_name>K-BILD questionnaire</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genomic DNA from blood; Blood for protein biomarkers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with chronic (fibrotic) hypersensitivity pneumonitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult outpatient subjects (18 years old or older) that fulfill the 2020 ATS/JRS/ALAT&#xD;
             diagnostic criteria of HP of at least moderate confidence (70% confidence or more).&#xD;
&#xD;
          2. Willingness to undergo the evaluations proposed in this protocol&#xD;
&#xD;
          3. HP diagnosis within the last 24 months&#xD;
&#xD;
          4. Presence of radiological or histological fibrosis:&#xD;
&#xD;
        4.a. Radiological fibrosis consists of unequivocal fine or coarse reticulation with&#xD;
        architectural lung distortion and/or traction bronchiectasis and/or honeycomb.&#xD;
&#xD;
        4.b. Unequivocal histopathological fibrosis evidenced on lung specimens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Presence of established connective tissue disease&#xD;
&#xD;
          3. Severe comorbidity impacting on the respiratory system as judged by the attending&#xD;
             physician (ex. congestive heart failure, neoplasm, post-COVID-19 sequelae)&#xD;
&#xD;
          4. Use of supplemental oxygen at rest&#xD;
&#xD;
          5. Dyspnea mMRC 4 (too breathless to leave the house or breathless when dressing or&#xD;
             undressing)&#xD;
&#xD;
          6. Unequivocal emphysematous pattern of HP on HRCT&#xD;
&#xD;
          7. Unequivocal pleuro-parenchymal fibroelastosis on the HRCT&#xD;
&#xD;
          8. Significant pulmonary arterial hypertension:&#xD;
&#xD;
        8.a. Signs of right ventricular failure by echodopplercardiogram or 8.b. Cardiac index &lt;&#xD;
        2L/min/m2 or right heart catheterism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leticia Kawano Dourado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCOR Research Institute, Hospital do Coracao, São Paulo, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan I Enghelmayer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Buenos Aires, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Otaola, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leticia Kawano-Dourado (PI), MD</last_name>
    <phone>+551130536611</phone>
    <phone_ext>8209</phone_ext>
    <email>ldourado@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flavia Kojima (Center Manager)</last_name>
    <phone>+551130536611</phone>
    <phone_ext>8236</phone_ext>
    <email>fkojima@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LABOX - Federal University of Santa Catarina</name>
      <address>
        <city>Santa Catarina</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAPOGEN - Federal University of Santa Catarina</name>
      <address>
        <city>Santa Catarina</city>
        <state>SC</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypersensitivity pneumonitis</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>interstitial lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Alveolitis, Extrinsic Allergic</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

